Clinical Takeaway
In this phase 3 trial of 820 adults with chronic low back pain, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks with extended follow-up periods lasting up to one year. The trial design, including a randomized withdrawal phase, was built to rigorously assess both sustained efficacy and safety across a large, diverse patient population. These findings contribute meaningful clinical evidence to the limited but growing body of research supporting cannabinoid-based treatment as a potential alternative to conventional analgesics for chronic low back pain.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by rigorously evaluating a full-spectrum cannabis extract for chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and substantial adverse effect profiles. The randomized, placebo-controlled design with 820 participants and extended follow-up provides level 1 evidence necessary to inform evidence-based prescribing decisions for a therapeutic class currently limited by regulatory uncertainty and insufficient clinical data. If VER-01 demonstrates superior efficacy and safety compared to placebo, it could offer clinicians a meaningful alternative for patients with CLBP who fail or cannot tolerate conventional analgesics.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial presents encouraging evidence that a standardized full-spectrum cannabis extract may offer meaningful pain relief for chronic low back pain, a condition where current pharmacologic options remain limited and often problematic. However, several important considerations warrant careful interpretation: the study’s primary outcomes and effect sizes are not fully detailed in the abstract provided, the comparison is limited to placebo rather than active comparators like NSAIDs or physical therapy, and long-term safety data beyond the extension phase remains unclear. The chemotype and cannabinoid profile of DKJ127 should be examined closely, as efficacy and tolerability can vary substantially across different cultivars and preparation methods. For clinical practice, while these results suggest cannabis extracts may warrant consideration in selected CLBP patients who have failed conventional approaches or cannot tolerate standard medications, this should not displace evidence-based first-line strategies including exercise, physical therapy, and psychological interventions, but rather complement them within a multimodal treatment framework.
| |